Antifibrotic effects of CXCL9 and its receptor CXCR3 in livers of mice and humans.

BACKGROUND & AIMS Fibrosis is the hallmark of chronic liver diseases, yet many aspects of its mechanism remain to be defined. Chemokines are ubiquitous chemotactic molecules that mediate many acute and chronic inflammatory conditions, and CXC chemokine genes colocalize with a locus previously shown to include fibrogenic genes. We investigated the roles of the chemokine CXCL9 and its receptor CXCR3 in liver fibrosis. METHODS The effects of CXCL variants on fibrogenesis were analyzed using samples from patients with hepatitis C virus infection and by induction of fibrosis in CXCR3(-/-) and wild-type mice. In mice, intrahepatic immune cell subsets were investigated and interferon gamma messenger RNA levels were measured at baseline and after injury. Human serum CXCL9 levels were measured and correlated with CXCL9 variant and fibrosis severity. The effects of stimulation with CXCL9 were investigated on human hepatic stellate cells (LX-2). RESULTS Specific CXCL9 variants were associated with liver fibrosis in mice and humans; CXCL9 serum concentrations correlated with genotypes and levels of fibrosis in patients. In contrast to other chemokines, CXCL9 exerted antifibrotic effects in vitro, suppressing collagen production in LX-2 cells. CXCR3(-/-) mice had increased liver fibrosis; progression was associated with decreased numbers of intrahepatic interferon gamma-positive T cells and reduced interferon gamma messenger RNA, indicating that CXCL9-CXCR3 regulates Th1-associated immune pathways. CONCLUSIONS This is the first description of a chemokine-based antifibrotic pathway in the liver; antifibrotic therapies might be developed to modulate CXC chemokine levels.

[1]  E. Haughton,et al.  Liver myofibroblasts regulate infiltration and positioning of lymphocytes in human liver. , 2009, Gastroenterology.

[2]  M. Heydtmann,et al.  Chemokines in the immunopathogenesis of hepatitis C infection , 2009, Hepatology.

[3]  C. Trautwein,et al.  Genetic variations of the chemokine scavenger receptor D6 are associated with liver inflammation in chronic hepatitis C. , 2008, Human immunology.

[4]  L. Chiriboga,et al.  Intrahepatic levels of CXCR3‐associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C , 2008, Hepatology.

[5]  Thomas E. Lane,et al.  Insertion of the CXC chemokine ligand 9 (CXCL9) into the mouse hepatitis virus genome results in protection from viral-induced encephalitis and hepatitis , 2008, Virology.

[6]  B. Engelhardt,et al.  Enhanced T cell transmigration across the murine liver sinusoidal endothelium is mediated by transcytosis and surface presentation of chemokines , 2008, Hepatology.

[7]  W. Bodmer,et al.  Common and rare variants in multifactorial susceptibility to common diseases , 2008, Nature Genetics.

[8]  M. Ostrowski,et al.  Disease progression in chronic hepatitis C: modifiable and nonmodifiable factors. , 2008, Gastroenterology.

[9]  S. Friedman,et al.  Mechanisms of hepatic fibrogenesis. , 2008, Gastroenterology.

[10]  T. Wynn,et al.  Cellular and molecular mechanisms of fibrosis , 2008, The Journal of pathology.

[11]  Zhigang Tian,et al.  Liver: An organ with predominant innate immunity , 2007, Hepatology.

[12]  Olivia T. Abar,et al.  A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C , 2007, Hepatology.

[13]  S. Kaneko,et al.  Blockade of IP-10/CXCR3 Promotes Progressive Renal Fibrosis , 2007, Nephron Experimental Nephrology.

[14]  K. Reddy,et al.  Final results of a double‐blind, placebo‐controlled trial of the antifibrotic efficacy of interferon‐γ1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis , 2007, Hepatology.

[15]  R. Strieter,et al.  The role of CXC chemokines in pulmonary fibrosis. , 2007, The Journal of clinical investigation.

[16]  S. Dooley,et al.  IFN-γ abrogates profibrogenic TGF-β signaling in liver by targeting expression of inhibitory and receptor Smads , 2007 .

[17]  Konstantinos N Lazaridis,et al.  Applying genomics to the study of complex disease. , 2007, Seminars in liver disease.

[18]  W. Jeong,et al.  STAT1 inhibits liver fibrosis in mice by inhibiting stellate cell proliferation and stimulating NK cell cytotoxicity , 2006, Hepatology.

[19]  M. Munks,et al.  CXCR3-Dependent Recruitment of Antigen-Specific T Lymphocytes to the Liver during Murine Cytomegalovirus Infection , 2006, Journal of Virology.

[20]  M. Grimm,et al.  Ras-induced modulation of CXCL10 and its receptor splice variant CXCR3-B in MDA-MB-435 and MCF-7 cells: relevance for the development of human breast cancer. , 2006, Cancer research.

[21]  S. Akira,et al.  Immunoprivileged status of the liver is controlled by Toll-like receptor 3 signaling. , 2006, The Journal of clinical investigation.

[22]  R. Ransohoff,et al.  The many roles of chemokines and chemokine receptors in inflammation. , 2006, The New England journal of medicine.

[23]  Jörg Köhl,et al.  Complement factor 5 is a quantitative trait gene that modifies liver fibrogenesis in mice and humans , 2005, Nature Genetics.

[24]  T. Asselah,et al.  Molecular profiling of early stage liver fibrosis in patients with chronic hepatitis C virus infection. , 2005, Virology.

[25]  Mark Daly,et al.  Haploview: analysis and visualization of LD and haplotype maps , 2005, Bioinform..

[26]  S. Friedman,et al.  Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis , 2004, Gut.

[27]  R. Homer,et al.  Regulation of pulmonary fibrosis by chemokine receptor CXCR3. , 2004, The Journal of clinical investigation.

[28]  Robert W. Williams,et al.  The nature and identification of quantitative trait loci: a community's view , 2003, Nature Reviews Genetics.

[29]  Peter Donnelly,et al.  A comparison of bayesian methods for haplotype reconstruction from population genotype data. , 2003, American journal of human genetics.

[30]  Sergio Romagnani,et al.  An Alternatively Spliced Variant of CXCR3 Mediates the Inhibition of Endothelial Cell Growth Induced by IP-10, Mig, and I-TAC, and Acts as Functional Receptor for Platelet Factor 4 , 2003, The Journal of experimental medicine.

[31]  F. Lammert,et al.  Genome-wide analysis of hepatic fibrosis in inbred mice identifies the susceptibility locus Hfib1 on chromosome 15. , 2002, Gastroenterology.

[32]  Nathaniel Rothman,et al.  Counterpoint: bias from population stratification is not a major threat to the validity of conclusions from epidemiological studies of common polymorphisms and cancer. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[33]  Xiaodan Ren,et al.  CXC Chemokine Expression After Stimulation with Interferon-&ggr; in Primary Rat Hepatocytes in Culture , 2002, Shock.

[34]  M. Serio,et al.  Signal Transduction by the Chemokine Receptor CXCR3 , 2001, The Journal of Biological Chemistry.

[35]  W. Hancock,et al.  Requirement of the Chemokine Receptor CXCR3 for Acute Allograft Rejection , 2000, The Journal of experimental medicine.

[36]  D. Rockey,et al.  Strain-specific differences in mouse hepatic wound healing are mediated by divergent T helper cytokine responses. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[37]  J. Hoofnagle,et al.  Classification of chronic hepatitis: Diagnosis, grading and staging , 1994, Hepatology.

[38]  L. Cosmi,et al.  Activation of p38(MAPK) mediates the angiostatic effect of the chemokine receptor CXCR3-B. , 2008, The international journal of biochemistry & cell biology.

[39]  Christian Weber,et al.  Heterophilic interactions of platelet factor 4 and RANTES promote monocyte arrest on endothelium. , 2005, Blood.